The Thailand ASEAN Point of Care Diagnostics Market was valued at $158.86 Million in 2025 and projected to reach to $201.24 Million by 2030, representing a compound annual growth rate of 4.8%. Thailand's point of care diagnostics market is poised for sustained expansion as the nation prioritizes healthcare accessibility and diagnostic efficiency.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Thailand's point of care diagnostics market is valued at USD 158.86 million in 2025, with projections reaching USD 201.24 million by 2030, representing a robust 4.8% CAGR driven by healthcare modernization initiatives.
Thailand is investing significantly in healthcare infrastructure modernization, particularly in rural regions, creating increased demand for rapid diagnostic solutions that reduce patient wait times and improve clinical outcomes.
The market is experiencing dual-track growth across both urban centers and rural settings, with point of care diagnostics becoming essential for Thailand's decentralized healthcare delivery model and primary care strengthening initiatives.
Thailand's 4.8% CAGR slightly outpaces the global ASEAN average of 4.7%, indicating the country's strategic positioning and accelerating adoption of point of care diagnostic technologies in Southeast Asia.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides a comprehensive range of POC diagnostics including glucose monitoring devices, cardiometabolic testing, and rapid infectious disease tests for hospitals, clinics, and home care settings. Emphasis on portable and easy-to-use solutions for chronic disease management. | Quick and reliable results for clinical and home use, supports continuous monitoring of chronic conditions, enhances patient self-management, scalable for high patient volumes, improves early intervention and treatment adherence. |
|
|
Offers multiplex POC platforms for infectious diseases, cardiometabolic testing, and molecular diagnostics in hospitals, outpatient centers, and emergency care units. Focuses on integrated systems that combine sample-to-result automation. | High diagnostic accuracy, rapid turnaround times, simultaneous detection of multiple biomarkers, supports early disease detection and timely treatment decisions, reduces repeat testing and workflow burden, facilitates point-of-care decision-making in critical care. |
|
|
Specializes in biochemistry-based POC testing for blood chemistry, electrolyte panels, liver and kidney function tests, and organ monitoring. Deploys compact and automated solutions in primary care centers, hospitals, and decentralized healthcare settings. | Automated, reliable, and reproducible results, reduces operator error, cost-effective, enables high-throughput testing, supports decentralized healthcare with minimal infrastructure, improves patient monitoring and disease management. |
|
|
Provides a diverse portfolio of POC diagnostic instruments and assay kits for infectious disease detection, hematology, glucose monitoring, and cardiovascular markers in hospitals and clinics. Offers solutions designed for high-volume, decentralized testing environments. | Rapid and accurate results, supports multiple diagnostic applications from a single platform, improves operational efficiency and workflow integration, enhances clinical decision-making, scalable for large patient populations, facilitates timely monitoring and intervention. |
|
|
Focuses on hematology and coagulation POC testing, with additional offerings for infectious diseases and chronic condition monitoring. Products are targeted at clinical laboratories, hospitals, and outpatient facilities for high-precision testing. | Accurate and reproducible results, easy-to-use compact platforms, supports timely patient management, enhances lab workflow efficiency, enables continuous monitoring of blood and coagulation parameters, facilitates early detection of abnormalities in critical care and routine testing. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | RESPIRATORY INFECTION TESTING PRODUCTS (Disease Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 4.7% from 2025 to 2030 |
| Largest Segment | BIOCHEMISTRY (Technology) |
| Market Size Base Year (Billions) | ~USD 1.08 (2025) |
| Revenue Forecast (Billions) | ~USD 1.36 (2030) |
| Segments Covered | Product, Type, Disease Type, Technology, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 51.81 | 51.74 | 51.98 | 52.53 | 53.32 | 55.84 | 57.62 | 59.79 | 2.6 |
| HOME CARE SETTINGS | 70.55 | 72.75 | 75.55 | 78.98 | 82.98 | 93.37 | 99.99 | 107.78 | 6.4 |
| HOSPITALS AND CRITICAL CARE CENTERS | 14.09 | 14.33 | 14.67 | 15.13 | 15.67 | 17.15 | 18.11 | 19.26 | 4.9 |
| OTHER END USERS | 4.04 | 3.98 | 3.95 | 3.95 | 3.96 | 4.07 | 4.17 | 4.29 | 1.7 |
| OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS | 7.89 | 7.96 | 8.09 | 8.27 | 8.5 | 9.15 | 9.59 | 10.12 | 4.1 |
| TOTAL | 148.38 | 150.76 | 154.23 | 158.86 | 164.43 | 179.59 | 189.48 | 201.24 | 4.8 |
Thailand's POC diagnostics market was valued at USD 158.86 million in 2025 and is expected to reach USD 201.24 million by 2030.
Thailand's POC diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2030.
Key drivers include Thailand's healthcare infrastructure modernization, rising chronic disease prevalence, government healthcare initiatives, and increasing demand for rapid diagnostic solutions in both urban and rural areas.
Thailand is experiencing accelerated growth in POC diagnostics for infectious disease screening, diabetes management, and cardiovascular risk assessment between 2025 and 2030.
Thailand's established medical device manufacturing base and strategic ASEAN location position it as a key growth hub for POC diagnostics, supporting both domestic adoption and regional distribution.
The study involved major activities in estimating the current market size for the ASEAN point of care diagnostics market. Exhaustive secondary research was done to collect information on the ASEAN point of care diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the ASEAN point of care diagnostics market.
The four steps involved in estimating the market size are:
In the secondary research process, various secondary sources, such as company annual reports, press releases, and investor presentations, white papers, certified publications, articles by recognized authors, gold-standard and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were referred to identify and collect information for this study.
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| PTS Diagnostics | Regional Sales Manager |
| EKF Diagnostics Holdings plc | Product Manager |
Both top-down and bottom-up approaches were used to estimate and validate the total size of the ASEAN point of care diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Point of care testing (POCT) includes tests designed to be used at or near the patient's site (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid & reliable diagnostic testing to obtain outcomes instantly, helping physicians/patients make care decisions remotely and rapidly.
Full forecast, segment splits, and company analysis for all ASEAN Point of Care Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report